Table 4

Metformin use after first estimated glomerular filtration rate (eGFR) decline among metformin initiators with first decline that persisted or worsened within 90 days

Baseline eGFR, mL/min/1.73 m2First eGFR decline, mL/min/1.73 m2Northern Denmark, N (%)UK, N (%)
Number of patientsNumber who continued use (%)Number who discontinued use (%)Number who switched use (%)Metformin users who stopped before eGFR decline (%)Metformin users who stopped before eGFR decline but restarted after eGFR declineIncomplete follow-up: outcome unknownNumber of patientsNumber who continued use (%)Number who discontinued use (%)Number who switched use (%)Metformin users who stopped before eGFR declineMetformin users who stopped before eGFR decline but restarted after eGFR declineIncomplete follow-up: outcome unknown (%)
≥6045–5916181139 (70.40)115 (7.11)20 (1.24)236 (14.59)80 (4.94)28 (1.73)24602083 (84.67)160 (6.50)47 (1.91)103 (4.19)41 (1.67)26 (1.06)
≥6030–448851 (57.95)7 (7.95)4 (4.55)14 (15.91)3 (3.41)9 (10.23)149107 (71.81)22 (14.77)9 (6.04)6 (4.03)05 (3.36)
≥6015–29801 (12.50)02 (25.00)05 (62.50)216 (28.57)7 (33.33)3 (14.29)01 (4.76)4 (19.05)
≥60<1531 (33.33)2 (66.67)000021 (50.00)00001 (50.00)
45–5930–44337239 (70.92)29 (8.61)8 (2.37)39 (11.57)12 (3.56)10 (2.97)14141127 (79.70)144 (10.18)60 (4.24)55 (3.89)19 (1.34)9 (0.64)
45–5915–29143 (21.43)2 (14.29)1 (7.14)1 (7.14)2 (14.29)5 (35.71)4626 (56.52)12 (26.09)2 (4.35)3 (6.52)03 (6.52)
45–59<15000000041 (25.00)1 (25.00)2 (50.00)000
30–4415–297741 (53.25)10 (12.99)2 (2.60)11 (14.29)5 (6.49)8 (10.39)373246 (65.95)73 (19.57)28 (7.51)14 (3.75)7 (1.88)5 (1.34)
30–44<151000001 (100.0)41 (25.00)1 (25.00)0002 (50.00)
15–29<1583 (37.50)004 (50.00)01 (12.50)91 (11.11)4 (44.44)2 (22.22)2 (22.22)00